BR0214301A - Compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods to treat diseases or conditions, to enhance a therapeutic effect of a snc agent, to improve a patient's recent memory, to determine the presence or absence of a gabaa receptor in a sample, and to alter gabaa receptor signal transduction activity, packaged pharmaceutical preparation, and use of a compound or salt - Google Patents
Compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods to treat diseases or conditions, to enhance a therapeutic effect of a snc agent, to improve a patient's recent memory, to determine the presence or absence of a gabaa receptor in a sample, and to alter gabaa receptor signal transduction activity, packaged pharmaceutical preparation, and use of a compound or saltInfo
- Publication number
- BR0214301A BR0214301A BR0214301-1A BR0214301A BR0214301A BR 0214301 A BR0214301 A BR 0214301A BR 0214301 A BR0214301 A BR 0214301A BR 0214301 A BR0214301 A BR 0214301A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- gabaa receptor
- salt
- alter
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
"COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA TRATAR DOENçAS OU CONDIçõES, PARA POTENCIALIZAR UM EFEITO TERAPêUTICO DE UM AGENTE DO SNC, PARA MELHORAR A MEMóRIA RECENTE DE UM PACIENTE, PARA DETERMINAR A PRESENçA OU AUSêNCIA DE UM RECEPTOR DE GABA~ A~ EM UMA AMOSTRA, E PARA ALTERAR A ATIVIDADE DE TRANSDUçãO DE SINAL DE RECEPTOR DE GABA~ A~, PREPARAçãO FARMACêUTICA ACONDICIONADA, E, USO DE UM COMPOSTO OU SAL". São descritas amidas de ácido III-pirrolo[3,2-p] piridina-3-carboxílico que ligam ao sítio de benzodiazepina de receptores GABA~ A~. Estes compostos podem ser usados para modular a ligação do ligando a receptores GABA~ A~, in vivo e in vitro, e são particularmente utilizáveis no tratamento de vários distúrbios do sistema nervoso central (CNS) em humanos, animais de estimação domesticados e animais de criação."COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING SICKNESS OR CONDITIONS, TO POTENTIALIZE A CNS AGENT, TO IMPROVE RECENTLY PRESENT PATIENT MEMORY, GABA ~ A ~ IN A SAMPLE, AND TO ALTER GABA ~ A ~ RECEIVER SIGNAL TRANSDUCTION ACTIVITY, PACKED PHARMACEUTICAL PREPARATION, AND USE OF A COMPOUND OR SALT ". III-pyrrolo [3,2-p] pyridine-3-carboxylic acid amides that bind to the benzodiazepine site of GABA-A? Receptors are described. These compounds can be used to modulate ligand binding to GABA-A A receptors in vivo and in vitro, and are particularly useful in the treatment of various central nervous system (CNS) disorders in humans, domesticated pets and pets. creation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33302701P | 2001-11-19 | 2001-11-19 | |
| PCT/US2002/037157 WO2003044018A1 (en) | 2001-11-19 | 2002-11-19 | 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0214301A true BR0214301A (en) | 2004-10-13 |
Family
ID=23300941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0214301-1A BR0214301A (en) | 2001-11-19 | 2002-11-19 | Compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods to treat diseases or conditions, to enhance a therapeutic effect of a snc agent, to improve a patient's recent memory, to determine the presence or absence of a gabaa receptor in a sample, and to alter gabaa receptor signal transduction activity, packaged pharmaceutical preparation, and use of a compound or salt |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1453831A1 (en) |
| JP (1) | JP2005516901A (en) |
| AU (1) | AU2002366092A1 (en) |
| BR (1) | BR0214301A (en) |
| CA (1) | CA2467542A1 (en) |
| MX (1) | MXPA04004711A (en) |
| WO (1) | WO2003044018A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2865208B1 (en) | 2004-01-16 | 2009-01-16 | Sanofi Synthelabo | 1,4-DIAZABICYCLO [3.2.1] OCTANECARBOXMIQUE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
| FR2890072A1 (en) * | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | New pyrrolopyridine derivatives are peroxisome proliferator activated receptor activators useful to treat e.g. hypertriglyceridimia, hyperlipidemia, hypercholesterolemia and diabetes |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| BR112015030399B8 (en) | 2013-06-05 | 2023-01-10 | C&C Res Lab | HETEROCYCLIC DERIVATIVES, USE OF SUCH DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH STAT3 PROTEIN ACTIVATION |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| WO2023082044A1 (en) * | 2021-11-09 | 2023-05-19 | 暨南大学 | 5-formyl heterocyclic amide compound and use thereof |
| CN116102549A (en) * | 2021-11-09 | 2023-05-12 | 暨南大学 | 5-aldehyde heterocyclic amide compound and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750702A (en) * | 1993-10-27 | 1998-05-12 | Neurogen Corporation | Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands |
-
2002
- 2002-11-19 JP JP2003545655A patent/JP2005516901A/en active Pending
- 2002-11-19 BR BR0214301-1A patent/BR0214301A/en not_active IP Right Cessation
- 2002-11-19 CA CA002467542A patent/CA2467542A1/en not_active Abandoned
- 2002-11-19 AU AU2002366092A patent/AU2002366092A1/en not_active Abandoned
- 2002-11-19 MX MXPA04004711A patent/MXPA04004711A/en active IP Right Grant
- 2002-11-19 EP EP02803679A patent/EP1453831A1/en not_active Withdrawn
- 2002-11-19 WO PCT/US2002/037157 patent/WO2003044018A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003044018A1 (en) | 2003-05-30 |
| EP1453831A1 (en) | 2004-09-08 |
| MXPA04004711A (en) | 2005-08-16 |
| CA2467542A1 (en) | 2003-05-30 |
| AU2002366092A1 (en) | 2003-06-10 |
| JP2005516901A (en) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0108977B8 (en) | azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof | |
| ATE267798T1 (en) | COMBINED ACTIVE INGREDIENTS AS A METHOD FOR TARGETED ACTIVE RELEASE | |
| ATE77747T1 (en) | 3-(AMINOPROPYL)METHYLPHOSPHIC ACID AS A THERAPEUTIC AGENT. | |
| DE60134453D1 (en) | Pharmaceutical compositions for the treatment of CNS and other diseases | |
| ES2096312T3 (en) | QUINUCLIDINE DERIVATIVE AS ANTAGONIST OF THE SUBSTANCE P. | |
| BR9815255A (en) | Modified botulism toxin, oral vaccine against botulism, oral vaccine against a selected agent and method for administering a therapeutic agent to an animal orally | |
| WO2002070473A3 (en) | Carboxamide derivatives as therapeutic agents | |
| DE60126980D1 (en) | THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC ILLNESSES | |
| CA2379695A1 (en) | Compounds for modulating the rage receptor | |
| HUP0002030A2 (en) | Use of glur5 receptorantagonists for the treatment of pain | |
| BR0313718A (en) | Compound, process for the preparation thereof, pharmaceutical composition, methods for treating a human or animal subject suffering from a condition which is cox-2 mediated and for treating a human or animal subject suffering from an inflammatory disorder, and, use of a compound | |
| IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
| PT946162E (en) | USING P-AMINOFENOL DERIVATIVES FOR THE PREPARATION OF USAL PHARMACEUTICAL COMPOSITIONS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| BR0214301A (en) | Compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods to treat diseases or conditions, to enhance a therapeutic effect of a snc agent, to improve a patient's recent memory, to determine the presence or absence of a gabaa receptor in a sample, and to alter gabaa receptor signal transduction activity, packaged pharmaceutical preparation, and use of a compound or salt | |
| DE69533194D1 (en) | PYRAZOLO (3.4g) CHINOXALINE AS A PDGF RECEPTOR PROTEIN TYROSIN KINASE INHIBITOR | |
| HK1024424A1 (en) | Methods of therapeutic administration of anti-cd40l compounds | |
| BR0307504A (en) | Pharmaceutically acceptable compound or salt, pharmaceutical composition, methods for treating disease, for enhancing a therapeutic effect of a snc agent, for enhancing short-term memory in a patient, for determining the presence or absence of gabaa receptors in a sample, and to alter gabaa receptor signal transducer activity, packaging, and use of a compound or salt | |
| WO2000048581A3 (en) | Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases | |
| BR0208241A (en) | Compound, pharmaceutical compositions, methods for treating anxiety, depression, a sleep disorder, attention deficit disorder, or alzheimer's dementia, to increase the potency of a therapeutic effect of a cns agent, to determine the presence or absence of gabaa receptor in a sample, and to alter the signal transduction activity of gabaa receptor, and, use of a compound | |
| BR0212249A (en) | Compound, pharmaceutical composition, method of treatment or prophylaxis of diseases, and use of a compound | |
| TNSN00034A1 (en) | NOVEL 2-AMINOPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| WO2004041809A3 (en) | Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands | |
| DE69514100D1 (en) | SUBSTITUTED CONDENSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | |
| BRPI0412908A (en) | compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods for treating anxiety, depression, a sleep disorder, attention deficit disorder or alzheimer's dementia, to enhance a therapeutic effect of a cns agent, to improve memory in a patient, to alter gabaa receptor signal transduction activity, and to determine the presence or absence of gabaa receptor in a sample, packaged pharmaceutical preparation, and use of a compound or salt | |
| RU95110774A (en) | Oligonulceotides, therapeutical compositions, and use of compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012. |